ClinicalTrials.gg
RecruitingNCT03936647RISEUpdated Aug 15, 2024

The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices

An interventional study of surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling and WEB embolization device in Intracranial Aneurysm, Brain Aneurysm and Unruptured Cerebral Aneurysm, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM) — 2 open to participants now, 3 under way, none of them phase 3. Intracranial Aneurysm · Centre hospitalier de l'Université de Montréal (CHUM).

Started
2019
the only one that year
No phase
8 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM), this one is the only one that started in 2019, is one of 8 with no phase, and was the 9th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

2 of the 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM) are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Intracranial Aneurysm by Centre hospitalier de l'Université de Montréal (CHUM), or all of them as a file.
02

Study summary

Intracranial bifurcation aneurysms are commonly repaired with surgical and with endovascular techniques. Wide-necked bifurcation aneurysms (WNBA) are a difficult subset of aneurysms to successfully repair endovascularly, and a number of treatment adjuncts have been designed. One particularly promising innovation is the WEB (Woven EndoBridge), which permits placement of an intra-saccular flow diverting mesh across the aneurysm neck, but which does not require anti-platelet agent therapy. Currently, which treatment option leads to the best outcome for patients with WNBA remains unknown. There is a need to offer treatment with the WEB within the context of a randomized care trial, to patients currently presenting with aneurysms thought to be suitable for the WEB.

03

Conditions studied

  • Intracranial Aneurysm
  • Brain Aneurysm
  • Unruptured Cerebral Aneurysm
  • Ruptured Cerebral Aneurysm
  • Cerebral Aneurysm

Browse trials for

Keywords

  • intracranial aneurysm
  • cerebral aneurysm
  • brain aneurysm
  • unruptured cerebral aneurysm
  • ruptured cerebral aneurysm
  • WEB embolization device
  • embolization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient with an intracranial aneurysm in whom WEB is considered an appropriate therapeutic option by the participating clinician
  • aneurysm of maximum diameter of 4-11 mm
  • may include (but are not restricted to) saccular bifurcation aneurysms of the middle cerebral artery, basilar bifurcation, carotid terminus, or anterior communicating artery aneurysms
  • Recurring, persistent aneurysm after previous treatment can be included so long as the treating physician judges the aneurysm morphology to be appropriate.
  • Ruptured aneurysms with WFNS ≤ 3

Exclusion criteria

Exclusion Criteria:

  • Absolute to surgery, endovascular treatment or anesthesia
  • Patients unable to give
  • diameter of the aneurysm ≤ 4 mm but ≥ 11 mm
  • Ruptured aneurysms with WFNS 4 or 5
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Standard conventional treatment (surgical or endovascular)

    Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.

    Procedure: surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling

  • Experimental
    WEB embolization device

    Endovascular treatment with WEB, including standard management of thrombo-embolic risk

    Device: WEB embolization device

Interventions

  • Proceduresurgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling

    Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.

  • DeviceWEB embolization device

    WEB embolization device

06

What researchers measure

Primary outcomes

  1. Number of participants with imaging showing that index aneurysm has reached complete or near occlusion

    complete or near complete occlusion of the aneurysm

    Time frame: 1 year from procedure

  2. Number of patients with a modified Rankin Score (mRS) below or equal to 2

    mRS ≤2 from evaluation (questionnaire) at follow-up visits throughout study. Grading score is to be assessed as such: Grade 0 No symptoms at all. Grade 1 No significant disability despite symptoms; able to carry out all usual duties and activities Grade 2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Grade 3 Moderate disability; requiring some help, but able to walk without assistance Grade 4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Grade 5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention Grade 6 Dead

    Time frame: 1 year from procedure

Secondary outcomes

  1. Number of participants with an interim modified Rankin Scale (mRS) below or equal to 2

    mRS ≤2 from evaluation (questionnaire) at discharge and follow-up visits throughout study. Grading score is to be assessed as such: Grade 0 No symptoms at all. Grade 1 No significant disability despite symptoms; able to carry out all usual duties and activities Grade 2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Grade 3 Moderate disability; requiring some help, but able to walk without assistance Grade 4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Grade 5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention Grade 6 Dead

    Time frame: within 1 week post-procedure, 1-3 months, and 12 months post-treatment

  2. Number of successful deployment of WEB device, coils or successful microsurgical, clipping, along with judgement of patency of parent arteries using imaging (depending on treatment received)

    Successful WEB deployment / aneurysm clipping / aneurysm coiling

    Time frame: within 1 hour from procedure

  3. Number of incidences of successful or unsuccesful patency of parent arteries using imaging

    Analysis of imaging to judge the patency of the parent arteries

    Time frame: within 1 hour from procedure

  4. Number of peri-operative complications

    Peri-operative complications (such as ischemic strokes and intracranial hemorrhages)

    Time frame: ≥5 days

  5. Number of aneurysm re-occurrences, (re-)rupture, or incomplete occlusion based on angiographic imaging

    Angiographic outcome (invasive or non-invasive imaging) results

    Time frame: 12 +/- 2 months

  6. Hospitalization time

    Hospital stay (number of days)

    Time frame: up to first post-procedure visit (around 1 month)

  7. Incidence of discharge destination by type

    Discharge disposition (home; other hospital; rehabilitation facility; death)

    Time frame: up to first post-procedure visit (around 1 month)

  8. Number of participants with stroke, neurological symptom or sign

    Any new stroke, neurological symptom or sign

    Time frame: within 12 +/- 2 months

  9. Number of index aneurysms necessitating or having received retreatment due to re-occurence

    Re-treatment of the index aneurysm as judged by imaging and interventionists neurosurgeons due to incomplete occlusion or hemorrhage

    Time frame: Within 12 +/- 2 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Jan 2025, 66 months after the start.

Of 59 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 134. This study's planned 66 months is above that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
May 3, 2019
StartActual
Jul 18, 2019
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2026
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03936647
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Jul 18, 2019
Primary completion
Jan 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Aug 15, 2024

Study contacts

daniela E Iancu, MD
Contact
daniela.iancu.med@ssss.gouv.qc.ca
514-890-8450
Guylaine Gevry, BSc
Contact
guylaine.gevry.chum@ssss.gouv.qc.ca
514-890-8000 ext. 27235

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion